577968-58-2

Upstream product

• 100-39-0 benzyl bromide 
• 151103-08-1 4-difluoromethoxy-3-hydroxybenzaldehyde 
• 75-45-6 Chlorodifluoromethane 
• 50773-56-3 3-benzyloxy-4-hydroxybenzaldehyde 
• 139-85-5 3,4-dihydroxybenzaldehyde 
• 65094-22-6 diethyl (bromodifluoromethyl)phosphonate 
• 621-59-0 isovanillin 
• 6346-05-0 3-benzyloxy-4-methoxybenzaldehyde 
• 100-44-7 benzyl chloride 

Downstream Products

• 1004753-11-0 3-(benzyloxy)-4-(difluoromethoxy)benzaldehyde oxime 
• 1622205-51-9 5-(benzyloxy)-6-(difluoromethoxy)-1H-indole 
• 151103-08-1 4-difluoromethoxy-3-hydroxybenzaldehyde 
• 1622205-50-8 (E)-2-(benzyloxy)-1-(difluoromethoxy)-4-(2-nitrovinyl)benzene 
• 1622205-49-5 C₂₄H₁₉ClF₂N₄O₄ 
• 1622204-18-5 6-(difluoromethoxy)-5-((2-(4-((4-hydroxypiperidin-1-yl)methyl)benzamide)pyridin-4-yl)oxy)-N-methyl-1H-indole-1-carboxamide 
• 577968-60-6 3-benzyloxy-4-difluoromethoxybenzyl chloride 
• 577968-59-3 3-benzyloxy-4-difluoromethoxybenzylalcohol 

Relevant academic research and scientific papers

Novel piperidine derivative and pharmaceutical use thereof

The present disclosure relates to a novel piperidine derivative and pharmaceutical use thereof. Specifically, provided is a compound represented by formula I, or a pharmaceutically acceptable salt thereof, or a stereoisomer, a rotamer, a tautomer or a deu

ANTI-INFLAMMATORY COMPOUND, AND PREPARATION AND USE THEREOF

The present invention provides an anti-inflammatory compound, which is a compound having a structure (I) as shown below: The compound is a target that is important for autoimmune activation, and that has strong inhibitory effect on PDE4 and penetrates the skin easily, and is a new type anti-inflammatory compound that is easily degraded.

New hybrid pyrazole and imidazopyrazole antinflammatory agents able to reduce ROS production in different biological targets

Several anti-inflammatory agents based on pyrazole and imidazopyrazole scaffolds and a large library of substituted catechol PDE4D inhibitors were reported by us in the recent past. To obtain new molecules potentially able to act on different targets involved in inflammation onset we designed and synthesized a series of hybrid compounds by linking pyrazole and imidazo-pyrazole scaffolds to differently decorated catechol moieties through an acylhydrazone chain. Some compounds showed antioxidant activity, inhibiting reactive oxygen species (ROS) elevation in neutrophils, and a good inhibition of phosphodiesterases type 4D and, particularly, type 4B, the isoform most involved in inflammation. In addition, most compounds inhibited ROS production also in platelets, confirming their ability to exert an antiinflammatory response by two independent mechanism. Structure–activity relationship (SAR) analyses evidenced that both heterocyclic scaffolds (pyrazole and imidazopyrazole) and the substituted catechol moiety were determinant for the pharmacodynamic properties, even if hybrid molecules bearing to the pyrazole series were more active than the imidazopyrazole ones. In addition, the pivotal role of the catechol substituents has been analyzed. In conclusion the hybridization approach gave a new serie of multitarget antiinflammatory compounds, characterized by a strong antioxidant activity in different biological targets.

Apremilast derivative and preparation method and application thereof

The invention discloses an Apremilast derivative and a preparation method and application thereof. The structural formula of the Apremilast derivative is shown in a formula I, wherein R1 is selected from any of the following groups: difluoromethyl, triflu

Drug compound for treating hepatopathy and application thereof

The invention discloses a drug compound for treating hepatopathy and application thereof. The drug compound specifically serves as a compound shown in general formula (I) or an optical isomer or a pharmaceutically-acceptable salt of the compound. The compound or the optical isomer or the pharmaceutically-acceptable salt of the compound has a good curative effect and low toxicity on hepatopathy, especially fatty liver. Experiments show that the compound has an obvious protective effect on zebrafish nonalcoholic fatty liver, so that the drug compound has a good application prospect in medicinesfor treatment or prevention of hepatopathy, especially fatty liver or liver fibrosis or liver cirrhosis.

Difluoromethoxy substituted diphenylethane and trans-distyrene derivative and preparation method and application thereof

The invention discloses a difluoromethoxy substituted diphenylethane and trans-distyrene derivative and a preparation method and application thereof. The 4 prime bit of B aromatic ring of diphenylethane/stilbene is subjected to chemical structural modification with difluoromethoxy, and meanwhile, the 3 prime bit is modified into substituents of nitro, amino or hydroxyl and the like. The difluoromethoxy substituted diphenylethane and trans-distyrene derivative is high in antitumor activity in vitro, physical, chemical and biological properties are changed by introduction of difluromethylation, and obvious inhibitory effect on tumor cells is achieved.

MONOCYCLIC PYRIDINE DERIVATIVE

The present invention provides a novel compound having FGFR inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same. Specifically, the present invention provides a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein n represents 0 to 2; A represents an arylene group or a heteroarylene group; G represents a single bond, an oxygen atom or —CH2—; E represents a nitrogen-containing non-aromatic heterocycle; R1 represents an alkoxy group or the like; R2 represents a hydrogen atom or the like; and R3 represents a hydrogen atom, an alkyl group, an alkoxy group or the like, with the proviso that when E represents an azetidine ring and R2 or R3 is present on a nitrogen atom on the azetidine ring, the R2 or R3 does not represent a hydrogen atom.

PHOSPHODIESTERASE INHIBITORS

The present invention relates to phosphodiesterase (PDE) type IV selective inhibitors. Compounds disclosed herein can be useful in the treatment of CNS diseases, AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases especially in humans. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and their use as PDE type IV selective inhibitors, are provided.

OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION

ABSTRACT The present invention provides a oxazole compound represented by Formula (1), or a salt thereof: wherein R1 is an aryl group which may have one or more substituents; R2 is an aryl group or a nitrogen atom-containing heterocyclic group each of which may have one or more substituents; and W is a divalent group represented by -Y1-A1- or -Y2-C(=O)- wherein Y1 is a group such as -C(=O)-, A1 is a group such as a lower alkylene group, and Y2 is a group such as a piperazinediyl group. The oxazole compound has a specific inhibitory action against phosphodiesterase 4.

PIPERIDINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT

A piperidine derivative of formula (I) (wherein all symbols are as described in the specification.) and an intermediate for the preparation thereof The compound of formula (I) has phosphodiesterase 4 inhibitory activity, and it is useful for the prevention and/or treatment of inflammatory diseases, diabetic diseases, allergic diseases, autoimmune diseases, ocular diseases, osteoporosis, bone fracture, osteoarthritis, obesity, bulimia, depression, Parkinson's disease, dementia, ischemia-reperfusion injury, leukemia, acquired immunodeficiency deficiency syndrome (AIDS), shock, systemically inflammatory responsive diseases (SIRS), etc.